MDT-AP-1204
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 41.04
- os_event
- true
- age_years
- 25
- sex
- M
- new_clusters
- S1
- umap1_2d
- -1.619048797
- umap2_2d
- -10.57467354
- umap1_3d
- -1.686741209
- umap2_3d
- -1.234132972
- umap3_3d
- 4.440611757
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.370
- ALLOGRAFT_REJECTION+0.360
- PANCREAS_BETA_CELLS+0.290
- INTERFERON_ALPHA_RESPONSE+0.280
- COAGULATION+0.250
- APICAL_SURFACE+0.220
- ESTROGEN_RESPONSE_LATE+0.200
- BILE_ACID_METABOLISM+0.160
- INFLAMMATORY_RESPONSE+0.160
- INTERFERON_GAMMA_RESPONSE+0.160
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- TGF_BETA_SIGNALING-0.500
- MITOTIC_SPINDLE-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.430
- G2M_CHECKPOINT-0.410
- MTORC1_SIGNALING-0.390
- DNA_REPAIR-0.370
- MYC_TARGETS_V2-0.370
- E2F_TARGETS-0.350
- OXIDATIVE_PHOSPHORYLATION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1473654 | GTEX | — | 0.925 |
| 2 | SRR1341057 | GTEX | — | 0.921 |
| 3 | SRR1455305 | GTEX | — | 0.919 |
| 4 | SRR1476186 | GTEX | — | 0.916 |
| 5 | MNG1148 | — | — | 0.915 |
| 6 | SRR1429725 | GTEX | — | 0.909 |
| 7 | SRR1440962 | GTEX | — | 0.908 |
| 8 | SRR1352554 | GTEX | — | 0.908 |
| 9 | SRR1421093 | GTEX | — | 0.906 |
| 10 | SJEPD001523_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |